Cargando…
Evolution-adjusted Tumor Pathophysiology: The Novel Language of Tumor Biology /
Combined modularized therapies for metastatic cancer are pointing to central problems of communication among 'systems participators'. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjuste...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Dordrecht :
Springer Netherlands : Imprint: Springer,
2013.
|
| Edición: | 1st ed. 2013. |
| Temas: | |
| Acceso en línea: | Texto Completo |
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-94-007-6866-6 | ||
| 003 | DE-He213 | ||
| 005 | 20220113152622.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 130702s2013 ne | s |||| 0|eng d | ||
| 020 | |a 9789400768666 |9 978-94-007-6866-6 | ||
| 024 | 7 | |a 10.1007/978-94-007-6866-6 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Evolution-adjusted Tumor Pathophysiology: |h [electronic resource] : |b The Novel Language of Tumor Biology / |c edited by Albrecht Reichle. |
| 250 | |a 1st ed. 2013. | ||
| 264 | 1 | |a Dordrecht : |b Springer Netherlands : |b Imprint: Springer, |c 2013. | |
| 300 | |a X, 453 p. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a text file |b PDF |2 rda | ||
| 505 | 0 | |a Preface.-I Introduction.-Communication ─ evolution ─ pathophysiology: An endogenous conjunction ─Instead of an introduction.-II Combined modularized therapies for metastatic tumors: Pointing to central problems of communication among 'systems participators' in tumors -- Applied systems biology for the control of metastatic cancer: Therapeutic top-down strategy for targeting the tumors' normativity -- Targeting the proangiogenic network in angiosarcomas: Biomodulatory therapy.- Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis.- Redirecting and modulating rationalizations of tumor-immanent normative functions in castration-resistant prostate ancer.-III Social engineering: Biomodulation, either endogenously initiated or by implementation of non-normative boundary conditions -- Non-hierarchically organized operations in malignancies: Stromal dysfunction induces hematopoetic malignancies.- Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective.- Proteome analysis identified the PPARc ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.IV The tumors' normativity: Reconstructing and operationalizing starting points for an evolution theory.- The philosophical quest of a cancer cell: Redefining existentialism.- The tumor's normativity: Normative structures, action norms and decision maxims as therapeutic targets for tumor therapy.- Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer.-V Evolution theory.- Evolution theory: Its practical relevance for understanding tumor development and specifying tumor therapy -- Modularity, subjectivity, intersubjectivity and normativity: Clinically applicable operative benchmarks -- Turning upside down the mode of science to emphasize and harness the impact of environmental communicative events. VI From genome- or organ-centric to rationalization-centric systematization of tumors -- Purposive-rational tumor therapy: Exploiting the tumor's 'living world' for diversifying, specifying and personalizing tumor therapy -- Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications.-VII Reconstruction of tumor-immanent normative functions, structures and decision maxims (hubs).- Bridging a diagnostic and therapeutic gap: Selecting, assessing and categorizing tumor-associated normative notions.- Personalizing tumor pathophysiology by diagnosing developmental problems in tumors with imaging techniques -- Biologic memory: Induction by metronomically administered combined modularized therapy.- VIII The tool of rationalizations constituting tumor-associated normative notions: The non-genomic counterpart of the tumor genome and therefore, an important therapeutic target for diversifying palliative care -- Diversifying and specifying palliative care for patients with metastatic cancer by therapeutic implementation of non-normative boundary conditions -- Targeting a hallmark of cancer: Simultaneous inflammation and tumor control for palliative care in metastatic cancer.-IX Novel clinical and pharmaceutical technology for bioengineering tumor response.- Combined modularized tumor therapy ─ tumor biology ─ and prognostic factors: Bioengineering tumor response.-X Objectifying the systems objects' subjectivity in biological systems: A novel reification of the scientific picture about the 'objective' world -- The systems objects' subjectivity as scientific object. Index. | |
| 520 | |a Combined modularized therapies for metastatic cancer are pointing to central problems of communication among 'systems participators'. A communication theory explains 'social engineering', endogenously induced or by implementing non-normative boundary conditions. Evolution-adjusted tumor pathophysiology is borne by an evolution theory, which contrasts narrative evolution histories. The tool of rationalizations constituting the tumor's normativity (inflammation, immune response etc.) represents the non-genomic counterpart of the tumor genome and should be additionally assessed during tumor staging. Evolution-adjusted tumor pathophysiology allows implementing applied systems biology, a novel clinical and pharmaceutical technology for bioengineering tumor response and personalizing tumor therapy. Combined modularized therapy, evolution-adjusted tumor pathophysiology, and 'universal' biomarkers concertedly address genetically based tumor heterogeneity. | ||
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Medicine-Research. | |
| 650 | 0 | |a Biology-Research. | |
| 650 | 0 | |a Bioinformatics. | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Biomedical Research. |
| 650 | 2 | 4 | |a Computational and Systems Biology. |
| 650 | 2 | 4 | |a Pharmaceutics. |
| 700 | 1 | |a Reichle, Albrecht. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9789400797871 |
| 776 | 0 | 8 | |i Printed edition: |z 9789400768673 |
| 776 | 0 | 8 | |i Printed edition: |z 9789400768659 |
| 856 | 4 | 0 | |u https://doi.uam.elogim.com/10.1007/978-94-007-6866-6 |z Texto Completo |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||